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urinary ﬂow rate. Physician’s diagnosis according to their expe-
rience, was recorded after each step A descriptive analysis was
conducted and validity and concordance were measured between
strategies. RESULTS: A total of 356 patients, mean age (SD) of
65.2 (8.4) years, with suspected BPH participated in the study.
Sensitivity, speciﬁcity, positive predictive value and negative pre-
dictive value were 91%, 65%, 95% and 50%, respectively. Per-
centage of agreement and kappa index between initial and ﬁnal
diagnosis were 87.9% and 0.5, respectively. CONCLUSIONS:
Concordance between initial diagnosis based on medical history,
I-PSS questionnaire, DRE and PSA with ﬁnal diagnosis of BPH
was high. This group of diagnostic procedures may be recom-
mended for BPH initial diagnosis in daily practice.
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OBJECTIVES: Despite current diabetes guidelines recommend-
ing increasingly stringent HbA1c targets, in the US approxi-
mately 60% of subjects are not controlled to target HbA1c
< 7%, with a typical 5-year delay. The purpose of this analysis
was to evaluate the effect of early achievement of glycemic
control on diabetes-related complications and costs.
METHODS: The Archimedes model was used to conduct a sim-
ulated clinical trial using patient-speciﬁc US NHANES data to
determine patient characteristics, current levels of glycemic
control and other CAD risk factors in people with diabetes. Sub-
jects with HbA1c > 7% were randomly assigned to four man-
agement strategies: status quo (SQ; maintaining current levels of
HbA1c but good compliance to guidelines for other CAD risk
factors), and reaching mean HbA1c < 7% within 6 months (MO),
12MO, or 24MO. The analysis focused on microvascular out-
comes. RESULTS: The model predicted that reducing HbA1c to
<7% in currently uncontrolled subjects would reduce the risk of
microvascular disease compared with SQ. Reaching HbA1c < 7%
within 6MO would reduce the 20-year risks of proteinuria
(52%), ESRD (44%, approximately 20,000 US cases prevented
p.a.), eye surgery (73%) and blindness (73%, approximately
17,500 cases prevented) compared with SQ. However, compared
with reaching HbA1c < 7% within 6MO, delaying to 24MO
increases these risks by 15%, 16%, 41% and 47%, respectively,
resulting in 3900 and 3000 more cases of ESRD and blindness,
respectively. Reaching target within 6MO would save approxi-
mately $2.3 billion p.a. compared with SQ. Delaying reaching
HbA1c < 7% to 24MO decreases these savings by approximately
$430 million. Beneﬁts were greater in patients with mean base-
line HbA1c > 9%. CONCLUSIONS: The Archimedes model pre-
dicts that in uncontrolled subjects, achieving HbA1c < 7% within
6MO would have important effects on microvascular outcomes
and costs. Delaying control to 24MO would reduce the amount
of beneﬁt gained. Bringing currently uncontrolled people into
control is important and should be achieved as rapidly as clini-
cally feasible.
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OBJECTIVES: Several trials of atomoxetine for the treatment of
attention deﬁcit hyperactivity disorder (ADHD) have employed
an active comparator arm of methylphenidate (MPH). This study
estimated efﬁcacy of atomoxetine and MPH in treating children
and adolescent with ADHD using combined patient-level data
from multiple trials. METHODS: Five randomized atomoxetine
trials contained an active comparator arm of MPH. Pooling of
all available data resulted in total 1078 patients, with 562 on
atomoxetine, 327 on MPH, and 189 on placebo. Because trials
excluded known non-responders to stimulant, stimulant exposed
patients may have a bias in favor of MPH. Subgroup analyses
were performed by stimulant history. The meta-regression is set
up as logistic regression for response. Response was deﬁned as
a ≥25% reduction in ADHD Rating Scale. In addition to treat-
ments, patient age, sex, duration of therapy, and trial effects were
controlled for. Random effect model was also estimated, but
ﬁxed effect was chosen. RESULTS: Response rates for stimulant
naïve patients were: 70.51% for atomoxetine, 77.27% for MPH,
and 41.46% for placebo. Response rate for each active treatment
was signiﬁcant, and signiﬁcantly different from placebo (p <
0.001). However, the two treatments were not statistically dif-
ferent by difference in means test (p = 0.069). In the exposed
group, response rates were: 62.17% for atomoxetine, 70.03%
for MPH, and 29.42% for placebo. Response rate for each active
treatment was signiﬁcant, and signiﬁcantly different from
placebo (p < 0.001). Difference between the two treatments, yet
again, was not statistically signiﬁcant (p = 0.214). CONCLU-
SION: To improve power and precision in the estimate, this
study pooled all available patient-level data from ﬁve random-
ized trials, and estimated response rate using the meta-regression
method. Efﬁcacy of atomoxetine and MPH were signiﬁcantly dif-
ferent from placebo. While response rate was higher for MPH,
response rates of the two active treatments were not statistically
different from each other.
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OBJECTIVE: To identify independent risk factors for renal
impairment in HRPC patients receiving ZA, we compared 
logistic regression and Cox proportional hazards models.
METHODS: A comprehensive medical record review was per-
formed, using electronic databases and paper records, in a large
tertiary oncology center. Inclusion criteria: ≥18 years, actively
treated, HRPC with BM, at least one ZA infusion (from 12/1999
to 4/2005), and at least one creatinine reading before and after
ﬁrst ZA infusion. Renal impairment was deﬁned as an increase
of ≥0.5mg/dL and ≥1.0mg/dL over baseline serum creatinine if
baseline was <1.4mg/dL and ≥1.4mg/dL, respectively; or any
doubling of baseline creatinine. Risk factor analysis was by logis-
tic regression with time adjustment, and by Cox model for time-
related binary outcome data. RESULTS: Among the 122 eligible
patients (mean age = 70.1), mean ZA treatment lasted 367.2 days
(mean 10.7 infusions per patient). About 59% of patients dis-
continued ZA; 21% due to renal complications. Twenty-nine
patients (23.8%, 95% CI: 16.2–31.3%) had renal impairment
during treatment; this is higher than previously reported in clin-
ical trials. Renal risk increased with extended ZA therapy (<6
months: 22.5%; ≥12 months: 23.5%; ≥24 months: 31.3%) and
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previous pamidronate treatment (45.8%). were identiﬁed. CON-
CLUSIONS: Although regression coefﬁcients are different, these
risk factors proved signiﬁcant in both multivariate models,
further supporting that these factors are likely important in pre-
dicting the renal impairment associated with ZA use in.
Podium Session IV
Development and Application of Methods and Concepts in
Statistics for Outcomes Research
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OBJECTIVES: Generation of population cost estimates for
event-censored data requires a sophisticated approach to account
for probability of incurring the event over time and different
patient characteristics. We investigated Medicare costs speciﬁ-
cally associated with all-cause graft failure following kidney
transplantation. We were particularly interested in developing
methods to study cost and see how these methods can inform
decision makers. METHODS: A modiﬁed two-part econometric
approach was used to determine Medicare claims attributable to
all-cause graft failure (including deaths). The approach was
accomplished in 3 steps: 1) Time was partitioned into discrete
intervals whereby intervals were chosen to reﬂect changes in the
relationship between cost and patient characteristics. Within
each interval, we established the predictive relationship of the
log-transformed costs with relevant factors based on those
patients whose graft failed in the interval; 2) Probability of graft
failure at the end of each interval was estimated using Cox
hazards regression; and 3) Results of steps 1 and 2 were com-
bined mathematically to obtain population-based estimate of
cost. Data on adult, primary transplants from cadaveric donors
between 1993 and 1998 were obtained from the United States
Renal Data System. Covariates modeled included donor and
recipient characteristics, and clinical variables including
immunosuppression therapies. Costs among different risk groups
were compared to evaluate their relative impact. RESULTS:
Expected Medicare claims attributed to all-cause graft failure at
3-years post-transplant was highest among patients who experi-
enced acute rejection by 6-months post transplant (AR: $62,749
vs. No AR: $47,787). CCONCLUSIONS: For event-censored
data, the estimation of cost associated with an event requires a
sophisticated approach. The modiﬁed two-part model may
provide more reliable estimates but the validity of this procedure
requires further research. Speciﬁc to transplantation, these esti-
mates may provide groundwork for further studies to address
the potential cost-effectiveness of various treatments to delay or
prevent graft failure.
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OBJECTIVES: Modeling approaches are used to estimate future
consequences and costs of diabetes and its complications, since
few studies provide data over a sufﬁcient duration or for all
costs, effects and populations. The Diabetes Mellitus Model
(DMM) predicts 10-year outcomes for patients with Type 1
(T1DM) and Type 2 (T2DM) diabetes based on published clin-
ical trials; these predictions mirror clinical trial outcomes. We
compared the DMM against real world, population-based epi-
demiological data from the Diabetes Audit and Research in
Tayside Scotland (DARTS) database. METHODS: We studied
two cohorts of 931 T1DM (46% male) and 12,907 T2DM (53%
male) patients, mean (±SD) age at diagnosis 21 (±14) and 61
(±13) years, respectively. Mean A1c for DARTS patients, diag-
nosed from 1 January 1993 to 31 December 2000, was derived
as a function of time since, and age at, diagnosis. Cohorts were
simulated using the DMM, and resulting A1c values were com-
pared with DARTS cohorts. Goodness of ﬁt was evaluated by
assessing bias, i.e. the underlying difference between DMM and
DARTS, and stochastic variation. RESULTS: For patients with
T1DM, changes in A1c over time were not predicted well by the
DMM; many of the differences between DARTS and DMM pre-
dicted A1c values were greater than 0.5% and the maximum bias
was 0.9%. For patients with T2DM, the changes were well pre-
dicted for all ages and age bands; maximum bias was 0.5%.
CONCLUSION: The DMM is successful in predicting real world
changes in A1c for T2DM; further work is needed to reproduce
real world changes in A1c for T1DM.
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OBJECTIVES: To evaluate the direction and relative magnitude
of a pharmacogenomics bias resulting from failure to adjust for
genetic heterogeneity in both treatment response (HT) and het-
erogeneity in progression of disease (HP) in decision models
extrapolating beyond short-term trial results. METHODS: We
constructed two Markov models with three health states (early-
stage, late-stage, dead), one adjusting and the other not adjust-
ing for genetic heterogeneity. We compared life expectancy gains
attributable to treatment resulting from both models and deﬁned
pharmacogenomics bias as percent deviation of treatment-
related life expectancy gains in the unadjusted model (UAM)
from those in the adjusted model (AM). We calculated the bias
as a function of underlying model parameters to create generic
results. We then applied our model to lipid-lowering therapy
with pravastatin in patients with coronary atherosclerosis, incor-
porating the inﬂuence of two TaqIB polymorphism variants (B1
and B2) on progression and drug efﬁcacy as reported in the DNA
substudy of the REGRESS trial. RESULTS: Our generic simula-
tion showed that a purely HT-related bias is negative (conserv-
ative) and a purely HP-related bias is positive (liberal). For many
typical scenarios, the absolute bias is smaller than 10%. In case
of joint HP and HT, the overall bias is likely triggered by the HP
component and reaches positive values >100% if fractions of
“fast progressors” and “strong treatment responders” are low.
In the pravastatin example, the UAM overestimated the true life-
years gained (LYG) by 5.5% (1.07 LYG vs. 0.99 LYG for 56-
year-old men). CONCLUSIONS: We have been able to predict
the pharmacogenomics bias jointly caused by heterogeneity in
progression of disease and heterogeneity in treatment response
as a function of characteristics of patients, disease, and treat-
ment. In the case of joint presence of both types of heterogene-
ity, models ignoring this heterogeneity may generate results that
overestimate the treatment beneﬁt.
